drugset
drugset / Trial / NCT06682130

Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

NCT06682130 ↗

Phase 2 Recruiting 40 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.

Timeline

Start
2024-11-10
Primary completion
2027-11-10
Completion
2029-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Glofitamab Monoclonal antibody 2.5 mg Intravenous
Subject Glofitamab Monoclonal antibody 10 mg Intravenous
Subject Glofitamab Monoclonal antibody 30 mg Intravenous
Background Cytarabine Small molecule 400 mg/m2 Intravenous
Background Etoposide Small molecule 200 mg/m2 Intravenous
Background Metformin Small molecule 140 mg/m2 Intravenous
Background Ottuzumab Unknown 1000 mg Intravenous
Background Simustine Unknown 250 mg/m2 Oral

Indications

diffuse large B-cell lymphoma